{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:11:49Z","timestamp":1790079109290,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd011123","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000}}],"reference-count":281,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011123.pub2","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T09:41:59Z","timestamp":1517910119000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Systemic treatments for metastatic cutaneous melanoma"],"prefix":"10.1002","volume":"2020","author":[{"given":"Sandro","family":"Pasquali","sequence":"additional","affiliation":[{"name":"Sarcoma Service; Fondazione IRCCS Istituto Nazionale dei Tumori; Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas V","family":"Hadjinicolaou","sequence":"additional","affiliation":[{"name":"Human Immunology Unit, Institute of Molecular Medicine, Radcliffe Department of Medicine; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna","family":"Chiarion Sileni","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit 2; Istituto Oncologico Veneto, IOV-IRCCS; Padova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Riccardo","family":"Rossi","sequence":"additional","affiliation":[{"name":"Melanoma and Sarcomas Unit; Istituto Oncologico Veneto, IOV-IRCCS; Padova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Mocellin","sequence":"additional","affiliation":[{"name":"Surgical Oncology Unit; Istituto Oncologico Veneto, IOV-IRCCS; Padova Italy"},{"name":"Istituto Oncologico Veneto; IOV-IRCCS; Padova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD011123.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<1979::AID-CNCR15>3.0.CO;2-G","article-title":"A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma","volume":"85","author":"Agarwala","year":"1999","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.2002.20.1.125","article-title":"Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma","volume":"20","author":"Agarwala","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"35","key":"10.1002\/14651858.CD011123.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1200\/JCO.2008.17.5448","article-title":"Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group","volume":"26","author":"Atkins","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.bjc.6600043","article-title":"Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)","volume":"86","author":"Atzpodien","year":"2002","journal-title":"British Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.2004.04.165","article-title":"Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study","volume":"22","author":"Avril","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/annonc\/mdi190","article-title":"Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group","volume":"16","author":"Bafaloukos","year":"2005","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00000421-198510000-00012","article-title":"Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine","volume":"8","author":"Bajetta","year":"1985","journal-title":"American Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1200\/JCO.1994.12.4.806","article-title":"Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma","volume":"12","author":"Bajetta","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/annonc\/mdl007","article-title":"Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma","volume":"17","author":"Bajetta","year":"2006","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0010|cit10","first-page":"454","article-title":"Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma","volume":"95","author":"Balch","year":"1984","journal-title":"Surgery"},{"issue":"29","key":"10.1002\/14651858.CD011123.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1200\/JCO.2006.06.0483","article-title":"Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group","volume":"24","author":"Bedikian","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdq438","article-title":"Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma","volume":"22","author":"Bedikian","year":"2011","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0013|cit13","first-page":"595","article-title":"Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma","volume":"60","author":"Bellett","year":"1976","journal-title":"Cancer Treatment Reports"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0014|cit14","first-page":"33","article-title":"Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study","volume":"60","author":"Beretta","year":"1976","journal-title":"Cancer Treatment Reports"},{"issue":"66","key":"10.1002\/14651858.CD011123.pub2-BIB0015|cit15","article-title":"DTIC and combination therapy for metastatic melanoma: a COG cooperative study","volume":"16","author":"Carter","year":"1975","journal-title":"Proceedings of the American Association for Cancer Research"},{"issue":"12","key":"10.1002\/14651858.CD011123.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.ejca.2014.03.289","article-title":"A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine inpatients with metastatic melanoma","volume":"50","author":"Carvajal","year":"2014","journal-title":"European Journal of Cancer"},{"issue":"9","key":"10.1002\/14651858.CD011123.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"46","key":"10.1002\/14651858.CD011123.pub2-BIB0018|cit18","first-page":"2697","article-title":"[Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone]","volume":"58","author":"Chauvergne","year":"1982","journal-title":"La Semaine des Hopitaux"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00008390-200104000-00015","article-title":"Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients","volume":"11","author":"Chiarion Sileni","year":"2001","journal-title":"Melanoma Research"},{"issue":"12","key":"10.1002\/14651858.CD011123.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/bjc.2011.178","article-title":"Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens","volume":"104","author":"Chiarion-Sileni","year":"2011","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/1097-0142(19800801)46:3<475::AID-CNCR2820460310>3.0.CO;2-1","article-title":"A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results","volume":"46","author":"Clunie","year":"1980","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD011123.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1056\/NEJM199208203270803","article-title":"Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen","volume":"327","author":"Cocconi","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00008390-200302000-00012","article-title":"Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized study","volume":"13","author":"Cocconi","year":"2003","journal-title":"Melanoma Research"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/1097-0142(197212)30:6<1457::AID-CNCR2820300607>3.0.CO;2-5","article-title":"Therapy of malignant melanoma with an imidazole carboxamide and bis-chloroethyl nitrosourea","volume":"30","author":"Costanza","year":"1972","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/1097-0142(197709)40:3<1010::AID-CNCR2820400308>3.0.CO;2-C","article-title":"Results with methyl-CCNU and DTIC in metastatic melanoma","volume":"40","author":"Costanza","year":"1977","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/mpo.2950100305","article-title":"Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study","volume":"10","author":"Costanzi","year":"1982","journal-title":"Medical and Pediatric Oncology"},{"issue":"7","key":"10.1002\/14651858.CD011123.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/mt.2013.79","article-title":"A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma","volume":"21","author":"Cui","year":"2013","journal-title":"Molecular Therapy"},{"issue":"13","key":"10.1002\/14651858.CD011123.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1200\/JCO.2003.10.039","article-title":"Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma","volume":"21","author":"Danson","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1479-5876-11-38","article-title":"Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-alpha in advanced malignant melanoma","volume":"11","author":"Daponte","year":"2013","journal-title":"Journal of Translational Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1060::AID-CNCR8>3.0.CO;2-2","article-title":"Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study","volume":"85","author":"Dorval","year":"1999","journal-title":"Cancer"},{"issue":"7","key":"10.1002\/14651858.CD011123.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2005.04.3216","article-title":"Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma","volume":"24","author":"Dummer","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/CMR.0b013e32830e3936","article-title":"Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group","volume":"18","author":"Eigentler","year":"2008","journal-title":"Melanoma Research"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/cncr.24686","article-title":"Results of a multicenter, randomized, double-blind phase 2\/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma","volume":"116","author":"Eisen","year":"2010","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD011123.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1200\/JCO.2002.07.044","article-title":"Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial","volume":"20","author":"Eton","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD011123.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.1991.9.8.1403","article-title":"Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma","volume":"9","author":"Falkson","year":"1991","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF01571406","article-title":"Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma","volume":"12","author":"Falkson","year":"1995","journal-title":"Medical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1200\/JCO.1998.16.5.1743","article-title":"Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study","volume":"16","author":"Falkson","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"10.1002\/14651858.CD011123.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2001.19.13.3194","article-title":"Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials","volume":"19","author":"Flaherty","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"18","key":"10.1002\/14651858.CD011123.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.2012.42.1529","article-title":"Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma","volume":"31","author":"Flaherty","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1002\/14651858.CD011123.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1002\/cncr.24576","article-title":"Results of a multicenter, randomized, double-blind, dose-evaluating phase 2\/3 study of lenalidomide in the treatment of metastatic malignant melanoma","volume":"115","author":"Glaspy","year":"2009","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00008390-200312000-00012","article-title":"Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686)","volume":"13","author":"Glover","year":"2003","journal-title":"Melanoma Research"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011123.pub2-BIB0044|cit44","first-page":"310","article-title":"Combined chemotherapy with or without interferon alpha N1 (IFN) for advanced malignant melanoma--a randomized pilot phase III study","volume":"27","author":"Gorbonova","year":"2000","journal-title":"Gan to Kagaku Ryoho. Cancer & Chemotherapy"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1445-2197.1978.tb05233.x","article-title":"Chemoimmunotherapy in disseminated melanoma and colorectal carcinoma","volume":"48","author":"Gough","year":"1978","journal-title":"Australian and New Zealand Journal of Surgery"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/annonc\/mdu054","article-title":"DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma","volume":"25","author":"Gupta","year":"2014","journal-title":"Annals of Oncology"},{"issue":"13","key":"10.1002\/14651858.CD011123.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1002\/cncr.28635","article-title":"A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma","volume":"120","author":"Hamid","year":"2014","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD011123.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1054\/bjoc.2001.1731","article-title":"Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)","volume":"84","author":"Hauschild","year":"2001","journal-title":"British Journal of Cancer"},{"issue":"17","key":"10.1002\/14651858.CD011123.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","article-title":"Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma","volume":"27","author":"Hauschild","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"9839","key":"10.1002\/14651858.CD011123.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD011123.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1093\/annonc\/mdv324","article-title":"A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma","volume":"26","author":"Hersh","year":"2015","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD011123.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"17","key":"10.1002\/14651858.CD011123.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2014.13943","article-title":"Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial","volume":"312","author":"Hodi","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/CMR.0b013e3283485ff0","article-title":"Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial","volume":"21","author":"Hofmann","year":"2011","journal-title":"Melanoma Research"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00008390-200202000-00013","article-title":"Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study","volume":"12","author":"Jelic","year":"2002","journal-title":"Melanoma Research"},{"issue":"8","key":"10.1002\/14651858.CD011123.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/bjc.1998.214","article-title":"Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma","volume":"77","author":"Johnston","year":"1998","journal-title":"British Journal of Cancer"},{"issue":"35","key":"10.1002\/14651858.CD011123.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"9001","DOI":"10.1200\/JCO.2005.01.1551","article-title":"Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group","volume":"23","author":"Kaufmann","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-4598-9-69","article-title":"A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy","volume":"9","author":"Kefford","year":"2010","journal-title":"Molecular Cancer"},{"issue":"7","key":"10.1002\/14651858.CD011123.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1200\/JCO.1997.15.7.2579","article-title":"Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group","volume":"15","author":"Keilholz","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"27","key":"10.1002\/14651858.CD011123.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1200\/JCO.2005.03.202","article-title":"Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group","volume":"23","author":"Keilholz","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1200\/JCO.2011.34.6270","article-title":"BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma","volume":"30","author":"Kim","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD011123.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/jnci\/82.12.1062","article-title":"Interferon alpha-2a and dacarbazine in melanoma","volume":"82","author":"Kirkwood","year":"1990","journal-title":"Journal of the National Cancer Institute"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0063|cit63","first-page":"16","article-title":"Comparison of the efficacy of imidazole-carboxamide and of a combination of nitrosomethylurea, vincristine and dactinomycin in disseminated melanoma","volume":"27","author":"Kogoniia","year":"1981","journal-title":"Voprosy Onkologii"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0064|cit64","first-page":"98","article-title":"Immuno-chemotherapy in patients with disseminated metastasizing stage III melanoma. Randomized study with methyl-CCNU versus C. parvum plus methyl-CCNU","volume":"1","author":"Kokoschka","year":"1978","journal-title":"Onkologie"},{"issue":"20","key":"10.1002\/14651858.CD011123.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"34","key":"10.1002\/14651858.CD011123.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2015.62.0500","article-title":"Randomized, placebo-controlled, phase III trial of yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and\/or stage IV melanoma: A trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697)","volume":"33","author":"Lawson","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD011123.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/oxfordjournals.annonc.a010762","article-title":"Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha","volume":"7","author":"Legha","year":"1996","journal-title":"Annals of Oncology"},{"issue":"9992","key":"10.1002\/14651858.CD011123.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF00175384","article-title":"Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma","volume":"2","author":"Lopez","year":"1984","journal-title":"Investigational New Drugs"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1200\/JCO.1984.2.3.164","article-title":"Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma","volume":"2","author":"Luikart","year":"1984","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD011123.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.2009.25.5208","article-title":"Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma","volume":"28","author":"Maio","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF00200210","article-title":"A phase III comparison of methyl-CCNU + vincristine with or without BCG + allogeneic tumor cells in metastatic melanoma","volume":"6","author":"Mastrangelo","year":"1979","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncology"},{"issue":"13","key":"10.1002\/14651858.CD011123.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.2007.14.8288","article-title":"Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group","volume":"26","author":"McDermott","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD011123.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdm331","article-title":"Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma","volume":"18","author":"Middleton","year":"2007","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD011123.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/annonc\/mdv308","article-title":"Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2015","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD011123.pub2-BIB0079|cit79","first-page":"1871","article-title":"Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma","volume":"49","author":"Miller","year":"1989","journal-title":"Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/1097-0142(197502)35:2<368::AID-CNCR2820350211>3.0.CO;2-C","article-title":"Comparison of the combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-1-triazino) imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanoma","volume":"35","author":"Moon","year":"1975","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/bjc.1976.140","article-title":"Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma","volume":"34","author":"Newlands","year":"1976","journal-title":"British Journal of Cancer"},{"issue":"32","key":"10.1002\/14651858.CD011123.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1200\/JCO.2008.17.1579","article-title":"Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma","volume":"27","author":"O'Day","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/bjc.2011.183","article-title":"A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma","volume":"105","author":"O'Day","year":"2011","journal-title":"British Journal of Cancer"},{"issue":"9","key":"10.1002\/14651858.CD011123.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1200\/JCO.2012.44.5585","article-title":"Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma","volume":"31","author":"O'Day","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD011123.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ejca.2011.04.030","article-title":"Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)","volume":"47","author":"Patel","year":"2011","journal-title":"European Journal of Cancer"},{"issue":"21","key":"10.1002\/14651858.CD011123.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/1097-0142(197909)44:3<899::AID-CNCR2820440317>3.0.CO;2-Y","article-title":"Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma","volume":"44","author":"Presant","year":"1979","journal-title":"Cancer"},{"issue":"7","key":"10.1002\/14651858.CD011123.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/1097-0142(19820401)49:7<1355::AID-CNCR2820490708>3.0.CO;2-W","article-title":"A randomized comparison of cyclophosphamide, DTIC with or without piperazinedione in metastatic malignant melanoma","volume":"49","author":"Presant","year":"1982","journal-title":"Cancer"},{"issue":"17","key":"10.1002\/14651858.CD011123.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/j.ejca.2006.08.012","article-title":"Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group","volume":"42","author":"Punt","year":"2006","journal-title":"European Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD011123.pub2-BIB0090|cit90","first-page":"1085","article-title":"Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study","volume":"62","author":"Ramseur","year":"1978","journal-title":"Cancer Treatment Reports"},{"issue":"18","key":"10.1002\/14651858.CD011123.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2007.10.8217","article-title":"Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma","volume":"25","author":"Ranson","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/CMR.0b013e3282f1d2c8","article-title":"Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial","volume":"17","author":"Reichle","year":"2007","journal-title":"Melanoma Research"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD011123.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2133.2004.06019.x","article-title":"Temozolomide and interferon alpha 2b in metastatic melanoma stage IV","volume":"151","author":"Richtig","year":"2004","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.2002.20.6.1600","article-title":"Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial","volume":"20","author":"Ridolfi","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02985163","article-title":"Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study","volume":"6","author":"Ringborg","year":"1989","journal-title":"Medical Oncology and Tumor Pharmacotherapy"},{"issue":"26","key":"10.1002\/14651858.CD011123.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD011123.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(13)70237-7","article-title":"Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study","volume":"14","author":"Robert","year":"2013","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"26","key":"10.1002\/14651858.CD011123.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD011123.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/1097-0142(19820601)49:11<2246::AID-CNCR2820491108>3.0.CO;2-D","article-title":"Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma","volume":"49","author":"Robidoux","year":"1982","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.1999.17.3.968","article-title":"Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b","volume":"17","author":"Rosenberg","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD011123.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1200\/JCO.1996.14.7.2083","article-title":"Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Rusthoven","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/annonc\/mdj138","article-title":"Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG","volume":"17","author":"Schadendorf","year":"2006","journal-title":"Annals of Oncology"},{"issue":"22","key":"10.1002\/14651858.CD011123.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00008390-199910000-00010","article-title":"Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma)","volume":"9","author":"Sertoli","year":"1999","journal-title":"Melanoma Research"},{"issue":"10","key":"10.1002\/14651858.CD011123.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.1993.11.10.1969","article-title":"Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma","volume":"11","author":"Sparano","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2007.11.9941","article-title":"Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group","volume":"26","author":"Testori","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD011123.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/0277-5379(86)90069-6","article-title":"Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma","volume":"22","author":"Thatcher","year":"1986","journal-title":"European Journal of Cancer & Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0112|cit112","first-page":"133","article-title":"Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial","volume":"3","author":"Thomson","year":"1993","journal-title":"Melanoma Research"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/030089168407000107","article-title":"Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guerin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma","volume":"70","year":"1984","journal-title":"Tumori"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S0959-8049(05)80351-X","article-title":"Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma","volume":"29A","author":"Verschraegen","year":"1993","journal-title":"European Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/0959-8049(94)90295-X","article-title":"A randomised trial of vindesine plus interferon-alpha 2b compared with interferon-alpha 2b or vindesine alone in the treatment of advanced malignant melanoma","volume":"30A","author":"Vorobiof","year":"1994","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00008390-200508000-00010","article-title":"Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma","volume":"15","author":"Vuoristo","year":"2005","journal-title":"Melanoma Research"},{"issue":"17","key":"10.1002\/14651858.CD011123.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1002\/cncr.24473","article-title":"Randomized phase 2\/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma","volume":"115","author":"Weber","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/1097-0142(197802)41:2<415::AID-CNCR2820410206>3.0.CO;2-S","article-title":"Combination chemotherapy in metastatic malignant melanoma: a randomized study of three DTIC-containing combination","volume":"41","author":"Wittes","year":"1978","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncology"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0121|cit121","first-page":"458","article-title":"Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma","volume":"13","author":"Young","year":"2001","journal-title":"Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/00008390-200310000-00012","article-title":"Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG)","volume":"13","author":"Zimpfer-Rechner","year":"2003","journal-title":"Melanoma Research"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/1078-0432.290.11.1","article-title":"Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104)","volume":"11","author":"Asemissen","year":"2005","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/0959-8049(94)00459-5","article-title":"Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen","volume":"31A","author":"Atzpodien","year":"1995","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.1995.13.4.910","article-title":"Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma","volume":"13","author":"Bleehen","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1002\/14651858.CD011123.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1002\/cncr.29622","article-title":"Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma","volume":"121","author":"Buchbinder","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/1097-0142(19830115)51:2<269::AID-CNCR2820510217>3.0.CO;2-6","article-title":"Randomized controlled trial of transfer factor in Stage II malignant melanoma","volume":"51","author":"Bukowski","year":"1983","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1524-4733.2007.00243.x","article-title":"Advanced cutaneous malignant melanoma: a systematic review of economic and quality-of-life studies","volume":"11","author":"Cashin","year":"2008","journal-title":"Value in Health"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00002371-199707000-00006","article-title":"A prospective randomized evaluation of the prophylactic use of low-dose dopamine in cancer patients receiving interleukin-2","volume":"20","author":"Cormier","year":"1997","journal-title":"Journal of Immunotherapy"},{"issue":"9","key":"10.1002\/14651858.CD011123.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"e107255","DOI":"10.1371\/journal.pone.0107255","article-title":"Cost-effectiveness of treatment strategies for BRAF mutated metastatic melanoma","volume":"9","author":"Curl","year":"2014","journal-title":"PLoS One"},{"issue":"22 Pt 1","key":"10.1002\/14651858.CD011123.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/1097-0142(19840315)53:6<1299::AID-CNCR2820530613>3.0.CO;2-4","article-title":"Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)","volume":"53","author":"Krementz","year":"1984","journal-title":"Cancer"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","article-title":"Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases","volume":"23","author":"Hughes","year":"2016","journal-title":"Annals of Surgical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0134|cit134","first-page":"521","article-title":"Promising results from phase III clinical trial of a peptide vaccine for advanced melanoma","volume":"1","author":"Hwu","year":"2009","journal-title":"Immunotherapy"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2217\/fon.10.66","article-title":"OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma","volume":"6","author":"Kaufman","year":"2010","journal-title":"Future Oncology"},{"issue":"8","key":"10.1002\/14651858.CD011123.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/0277-5379(82)90069-4","article-title":"N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group","volume":"18","author":"Kleeberg","year":"1982","journal-title":"European Journal of Cancer & Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00008390-199510000-00010","article-title":"Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up","volume":"5","author":"Lattanzi","year":"1995","journal-title":"Melanoma Research"},{"issue":"10","key":"10.1002\/14651858.CD011123.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1093\/annonc\/mdt291","article-title":"Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)","volume":"24","author":"McDermott","year":"2013","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00008390-200302000-00016","article-title":"A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma","volume":"13","author":"Mornex","year":"2003","journal-title":"Melanoma Research"},{"issue":"8","key":"10.1002\/14651858.CD011123.pub2-BIB0140|cit140","first-page":"929","article-title":"Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases","volume":"128","author":"Quirt","year":"1983","journal-title":"Canadian Medical Association Journal"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.1999.17.2.651","article-title":"Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma","volume":"17","author":"Richards","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/annonc\/mdm565","article-title":"Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)","volume":"19","author":"Spieth","year":"2008","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/mpo.2950010205","article-title":"A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma","volume":"1","author":"Van Dyk","year":"1975","journal-title":"Medical and Pediatric Oncology"},{"issue":"8","key":"10.1002\/14651858.CD011123.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1245\/s10434-007-9389-5","article-title":"A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma","volume":"14","author":"Varker","year":"2007","journal-title":"Annals of Surgical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD011123.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/1097-0142(19950815)76:4<687::AID-CNCR2820760424>3.0.CO;2-M","article-title":"The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2","volume":"76","author":"Yang","year":"1995","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0147|cit147","unstructured":"A phase 3 study to compare efficacy and safety of masitinib to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of C-Kit clinicaltrials.gov\/ct2\/show\/NCT01280565"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0148|cit148","unstructured":"Phase 3 trial in subjects with metastatic melanoma comparing 3 mg\/kg ipilimumab versus 10 mg\/kg ipilimumab clinicaltrials.gov\/ct2\/show\/NCT01515189"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0149|cit149","unstructured":"Study comparing the efficacy of MEK162 versus dacarbazine in unresectable or metastatic NRAS mutation-positive melanoma clinicaltrials.gov\/ct2\/show\/NCT01763164"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0150|cit150","unstructured":"Study comparing combination of LGX818 plus MEK162 versus vemurafenib and LGX818 monotherapy in BRAF mutant melanoma (COLUMBUS) clinicaltrials.gov\/ct2\/show\/NCT01909453"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0151|cit151","unstructured":"Ipilimumab with or without dabrafenib, trametinib, and\/or nivolumab in treating patients with melanoma that is metastatic or cannot be removed by surgery clinicaltrials.gov\/ct2\/show\/NCT01940809"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0152|cit152","unstructured":"Safety and efficacy study of vemurafenib and high-dose interferon alfa-2b in melanoma (12-107) clinicaltrials.gov\/ct2\/show\/NCT01943422"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0153|cit153","unstructured":"A study of the safety and efficacy of pembrolizumab (MK-3475) in combination with trametinib and dabrafenib in participants with advanced melanoma (MK-3475-022\/KEYNOTE-022) clinicaltrials.gov\/ct2\/show\/NCT02130466"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0154|cit154","unstructured":"Dabrafenib and trametinib followed by ipilimumab and nivolumab or ipilimumab and nivolumab followed by dabrafenib and trametinib in treating patients with stage III-IV BRAFV600 melanoma clinicaltrials.gov\/ct2\/show\/NCT02224781"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0155|cit155","unstructured":"Study comparing TIL to standard ipilimumab in patients with metastatic melanoma (TIL) clinicaltrials.gov\/ct2\/show\/NCT02278887"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0156|cit156","unstructured":"Nivolumab and ipilimumab with or without sargramostim in treating patients with stage III-IV melanoma that cannot be removed by surgery clinicaltrials.gov\/ct2\/show\/NCT02339571"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0157|cit157","unstructured":"Efficacy study of nivolumab compared to ipilimumab in prevention of recurrence of melanoma after complete resection of stage IIIb\/c or stage IV melanoma (CheckMate 238) clinicaltrials.gov\/ct2\/show\/NCT02388906"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0158|cit158","unstructured":"Access study of trametinib for subjects with advanced unresectable (Stage IIIc) or distant metastatic (Stage IV) BRAF V600E\/K mutation positive cutaneous melanoma clinicaltrials.gov\/ct2\/show\/NCT02416232"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0159|cit159","unstructured":"A study of fotemustine(FTM) vs FTM and ipilimumab (IPI) or IPI and nivolumab in melanoma brain metastasis (NIBIT-M2) clinicaltrials.gov\/ct2\/show\/NCT02460068"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0160|cit160","unstructured":"High-dose recombinant interferon alfa-2B, ipilimumab, or pembrolizumab in treating patients with stage III-IV high risk melanoma that has been removed by surgery clinicaltrials.gov\/ct2\/show\/NCT02506153"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0161|cit161","unstructured":"Nivolumab combined with ipilimumab followed by nivolumab monotherapy as first-line treatment for patients with advanced melanoma (CheckMate 401) clinicaltrials.gov\/ct2\/show\/NCT02599402"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0162|cit162","unstructured":"Study comparing pembrolizumab with dual MAPK pathway inhibition plus pembrolizumab in melanoma patients (IMPemBra) clinicaltrials.gov\/ct2\/show\/NCT02625337"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0163|cit163","unstructured":"A study of two different dose combinations of nivolumab in combination with ipilimumab in subjects with previously untreated, unresectable or metastatic melanoma clinicaltrials.gov\/ct2\/show\/NCT02714218"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0164|cit164","unstructured":"A phase 3 study of pembrolizumab + epacadostat or placebo in subjects with unresectable or metastatic melanoma (Keynote-252 \/ ECHO-301) clinicaltrials.gov\/ct2\/show\/NCT02752074"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0165|cit165","unstructured":"Duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP) clinicaltrials.gov\/ct2\/show\/NCT02821013"},{"issue":"7223","key":"10.1002\/14651858.CD011123.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","article-title":"Calculating the number needed to treat for trials where the outcome is time to an event","volume":"319","author":"Altman","year":"1999","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2288-2-3","article-title":"Meta-analysis, Simpson's paradox, and the number needed to treat","volume":"2","author":"Altman","year":"2002","journal-title":"BMC Medical Research Methodology"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/sj.bjc.6606030","article-title":"Targeting BRAF for patients with melanoma","volume":"104","author":"Arkenau","year":"2011","journal-title":"British Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jare.2017.06.006","article-title":"Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review","volume":"8","author":"Al-Abd","year":"2017","journal-title":"Journal of Advanced Research"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0170|cit170","unstructured":"Australian Cancer Network Melanoma Guidelines Revision Working Party Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand (CP111) Wellington 2008"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/annonc\/mdl007","article-title":"Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma","volume":"17","author":"Bajetta","year":"2006","journal-title":"Annals of Oncology"},{"issue":"16","key":"10.1002\/14651858.CD011123.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"36","key":"10.1002\/14651858.CD011123.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1359-6101(01)00022-3","article-title":"Interferon-alpha in tumor immunity and immunotherapy","volume":"13","author":"Belardelli","year":"2002","journal-title":"Cytokine & Growth Factor Reviews"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00520-002-0419-3","article-title":"The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma","volume":"11","author":"Beusterien","year":"2003","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/9780470743386.ch25","volume-title":"Introduction to Meta-analysis","author":"Borenstein","year":"2009"},{"issue":"14","key":"10.1002\/14651858.CD011123.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/85.14.1138","article-title":"Assessing the reliability of two toxicity scales: implications for interpreting toxicity data","volume":"85","author":"Brundage","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1158\/1078-0432.CCR-15-0460","article-title":"Molecular pathways: mitochondrial reprogramming in tumor progression and therapy","volume":"22","author":"Caino","year":"2016","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0179|cit179","unstructured":"Cancer Research UK 2017 General cancer information www.about-cancer.cancerresearchuk.org\/about-cancer\/cancer-in-general\/treatment\/targeted-cancer-drugs\/types\/monoclonal-antibodies"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1634\/theoncologist.7-3-181","article-title":"Interpreting measures of treatment effect in cancer clinical trials","volume":"7","author":"Case","year":"2002","journal-title":"Oncologist"},{"issue":"10","key":"10.1002\/14651858.CD011123.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PloS One"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/CMR.0b013e328346554d","article-title":"Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials","volume":"21","author":"Chi","year":"2011","journal-title":"Melanoma Research"},{"issue":"11","key":"10.1002\/14651858.CD011123.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0959-8049(03)00372-1","article-title":"Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients","volume":"39","author":"Chiarion-Sileni","year":"2003","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"49","key":"10.1002\/14651858.CD011123.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"81493","DOI":"10.18632\/oncotarget.13277","article-title":"The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis","volume":"7","author":"CiRen","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"10.1002\/14651858.CD011123.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/0959-8049(93)90115-V","article-title":"Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma","volume":"29A","author":"Coates","year":"1993","journal-title":"European Journal of Cancer"},{"issue":"6892","key":"10.1002\/14651858.CD011123.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamaoncol.2016.4877","article-title":"Systemic therapy for previously untreated advanced BRAF-mutated melanoma: a systematic review and network meta-analysis of randomized clinical trials","volume":"3","author":"Devji","year":"2017","journal-title":"JAMA Oncology"},{"issue":"9","key":"10.1002\/14651858.CD011123.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1470-2045(12)70324-8","article-title":"Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial","volume":"13","author":"Di Giacomo","year":"2012","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jrsm.1085","article-title":"Assessing key assumptions of network meta-analysis: a review of methods","volume":"4","author":"Donegan","year":"2013","journal-title":"Research Synthesis Methods"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing","volume":"16","author":"Edlundh-Rose","year":"2006","journal-title":"Melanoma Research"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD011123.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"vi30","DOI":"10.1093\/annonc\/mdp250","article-title":"Utility of adjuvant systemic therapy in melanoma","volume":"20","author":"Eggermont","year":"2009","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1002\/14651858.CD011123.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"International journal of cancer"},{"issue":"18","key":"10.1002\/14651858.CD011123.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"The New England journal of medicine"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.2012.42.1529","article-title":"Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma","volume":"31","author":"Flaherty","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1365-2133.2012.11125.x","article-title":"Melanoma incidence and mortality in Europe: new estimates, persistent disparities","volume":"167","author":"Forsea","year":"2012","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","article-title":"Systematic review of medical treatment in melanoma: current status and future prospects","volume":"16","author":"Garbe","year":"2011","journal-title":"Oncologist"},{"issue":"16","key":"10.1002\/14651858.CD011123.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2174\/0929867324666170112112734","article-title":"Kinase inhibitors in multitargeted cancer therapy","volume":"24","author":"Gentile","year":"2017","journal-title":"Current Medicinal Chemistry"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0199|cit199","unstructured":"Gorry C McCullagh L O'Donnell H Barrett S Schmitz S Barry M Neoadjuvant treatment for malignant and metastatic cutaneous melanoma Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD011123.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/annonc\/mdu154","article-title":"Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine","volume":"25","author":"Grob","year":"2014","journal-title":"Annals of Oncology"},{"issue":"13","key":"10.1002\/14651858.CD011123.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","article-title":"Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial","volume":"16","author":"Grob","year":"2015","journal-title":"Lancet Oncology"},{"issue":"21","key":"10.1002\/14651858.CD011123.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"7650","key":"10.1002\/14651858.CD011123.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE; an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD011123.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1245\/s10434-013-2999-1","article-title":"Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma","volume":"20","author":"Gyorki","year":"2013","journal-title":"Annals of Surgical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ctrv.2007.10.003","article-title":"Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review","volume":"34","author":"Hamm","year":"2008","journal-title":"Cancer Treatment Reviews"},{"issue":"17","key":"10.1002\/14651858.CD011123.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","article-title":"Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma","volume":"27","author":"Hauschild","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0208|cit208","unstructured":"Higgins JPT Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"7","key":"10.1002\/14651858.CD011123.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.2000.18.7.1474","article-title":"Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma","volume":"18","author":"Hillner","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD011123.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1177\/0272989X13481110","article-title":"Comparing Bayesian and frequentist approaches for multiple outcome mixed treatment comparisons","volume":"33","author":"Hong","year":"2013","journal-title":"Medical Decision Making"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00008390-200102000-00009","article-title":"Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials","volume":"11","author":"Huncharek","year":"2001","journal-title":"Melanoma Research"},{"issue":"34","key":"10.1002\/14651858.CD011123.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1200\/JCO.2007.12.0253","article-title":"Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients","volume":"25","author":"Ives","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clbc.2015.04.005","article-title":"Tailored tamoxifen treatment for breast cancer patients: a perspective","volume":"15","author":"Jager","year":"2015","journal-title":"Clin Breast Cancer"},{"issue":"10043","key":"10.1002\/14651858.CD011123.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","article-title":"Antiangiogenic therapy in oncology: current status and future directions","volume":"388","author":"Jayson","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/sonc.2002.35240","article-title":"Biochemotherapy for advanced melanoma","volume":"29","author":"Keilholz","year":"2002","journal-title":"Seminars in Oncology"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1081\/CNV-120025084","article-title":"Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine","volume":"21","author":"Kiebert","year":"2003","journal-title":"Cancer Investigation"},{"issue":"20","key":"10.1002\/14651858.CD011123.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1200\/JCO.2007.14.6423","article-title":"Next generation of immunotherapy for melanoma","volume":"26","author":"Kirkwood","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0220|cit220","first-page":"309","article-title":"Immunotherapy of cancer in 2012","volume":"62","author":"Kirkwood","year":"2012","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1158\/1078-0432.CCR-11-1491","article-title":"Phase II, open-label, randomized trial of the MEK1\/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma","volume":"18","author":"Kirkwood","year":"2012","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ejca.2012.11.004","article-title":"BRAF inhibitor activity in V600R metastatic melanoma","volume":"49","author":"Klein","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2174\/092986707779941078","article-title":"Drug resistance in melanoma: new perspectives","volume":"14","author":"La Porta","year":"2007","journal-title":"Current Medicinal Chemistry"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2174\/156800909788166574","article-title":"Mechanism of drug sensitivity and resistance in melanoma","volume":"9","author":"La Porta","year":"2009","journal-title":"Current Cancer Drug Targets"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.det.2012.04.001","article-title":"Update on the current state of melanoma incidence","volume":"30","author":"Little","year":"2012","journal-title":"Dermatologic Clinics"},{"issue":"10","key":"10.1002\/14651858.CD011123.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD011123.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncology"},{"issue":"11","key":"10.1002\/14651858.CD011123.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/01.sla.0000152014.89434.96","article-title":"Histopathologic excision margin affects local recurrence rate: analysis of 2681 patients with melanomas < or =2 mm thick","volume":"241","author":"McKinnon","year":"2005","journal-title":"Annals of Surgery"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"e86194","DOI":"10.1371\/journal.pone.0086194","article-title":"Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma","volume":"9","author":"Meckbach","year":"2014","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0232|cit232","unstructured":"Melanoma Institute Australia Glossary www.melanoma.org.au\/understanding-melanoma\/glossary\/braf\/"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/pcmr.12132","article-title":"Paradoxical oncogenesis: are all BRAF inhibitors equal?","volume":"26","author":"Menzies","year":"2013","journal-title":"Pigment Cell & Melanoma Research"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0234|cit234","first-page":"f2914","article-title":"Demystifying trial networks and network meta-analysis","volume":"346","author":"Mills","year":"2013","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0235|cit235","first-page":"61","article-title":"Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines","volume":"1653","author":"Mocellin","year":"2003","journal-title":"Biochim Biophys Acta. 2003 Dec 5;1653(2):61-71"},{"issue":"11","key":"10.1002\/14651858.CD011123.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1470-2045(04)01610-9","article-title":"Part I: Vaccines for solid tumours","volume":"5","author":"Mocellin","year":"2004","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2741\/1698","article-title":"Cancer vaccines: the challenge of developing an ideal tumor killing system","volume":"10","author":"Mocellin","year":"2005","journal-title":"Frontiers in Bioscience"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/med.20110","article-title":"Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines","volume":"28","author":"Mocellin","year":"2008","journal-title":"Medicinal Research Reviews"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.2174\/092986709789909648","article-title":"Peptide-based anticancer vaccines: recent advances and future perspectives","volume":"16","author":"Mocellin","year":"2009","journal-title":"Curr Med Chem"},{"issue":"7","key":"10.1002\/14651858.CD011123.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jnci\/djq009","article-title":"Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis","volume":"102","author":"Mocellin","year":"2010","journal-title":"Journal of the National Cancer Institute"},{"issue":"8","key":"10.1002\/14651858.CD011123.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"e11965","DOI":"10.1371\/journal.pone.0011965","article-title":"Targeted Therapy Database (TTD): a model to match patient's molecular profile with current knowledge on cancer biology","volume":"5","author":"Mocellin","year":"2010","journal-title":"PloS One"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/SLA.0b013e318207a331","article-title":"The impact of surgery on survival of patients with cutaneous melanoma: revisiting the role of primary tumor excision margins","volume":"253","author":"Mocellin","year":"2011","journal-title":"Annals of Surgery"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0243|cit243","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008955","article-title":"Interferon alpha for the adjuvant treatment of cutaneous melanoma","author":"Mocellin","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cytogfr.2013.01.003","article-title":"Coinhibitory molecules in cancer biology and therapy","volume":"24","author":"Mocellin","year":"2013","journal-title":"Cytokine & Growth Factor Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0245|cit245","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.bbcan.2013.05.003","article-title":"CTLA-4 blockade and the renaissance of cancer immunotherapy","volume":"1836","author":"Mocellin","year":"2013","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0246|cit246","first-page":"127","article-title":"Dacarbazine","volume":"12","author":"National Toxicology Program","year":"2011","journal-title":"Report on carcinogens : carcinogen profiles \/ U.S. Dept. of Health and Human Services, Public Health Service, National Toxicology Program"},{"issue":"24","key":"10.1002\/14651858.CD011123.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"29","key":"10.1002\/14651858.CD011123.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.2174\/092986710793176393","article-title":"The anticancer face of interferon alpha (IFN-alpha): from biology to clinical results, with a focus on melanoma","volume":"17","author":"Pasquali","year":"2010","journal-title":"Current Medicinal Chemistry"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/SLA.0b013e31828421e1","article-title":"The importance of adequate primary tumor excision margins and sentinel node biopsy in achieving optimal locoregional control for patients with thick primary melanomas","volume":"258","author":"Pasquali","year":"2013","journal-title":"Annals of Surgery"},{"issue":"5","key":"10.1002\/14651858.CD011123.pub2-BIB0250|cit250","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011123","article-title":"Systemic treatments for metastatic cutaneous melanoma","author":"Pasquali","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ctrv.2017.01.006","article-title":"Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis","volume":"54","author":"Pasquali","year":"2017","journal-title":"Cancer Treatment Reviews"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1477-7525-10-66","article-title":"Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment","volume":"10","author":"Revicki","year":"2012","journal-title":"Health and Quality of Life Outcomes"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0253|cit253","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan) 2014"},{"issue":"6","key":"10.1002\/14651858.CD011123.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.2002.20.6.1600","article-title":"Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial","volume":"20","author":"Ridolfi","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD011123.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PloS One"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0257|cit257","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005413.pub2","article-title":"Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma","author":"Sasse","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD011123.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"vi41","DOI":"10.1093\/annonc\/mdp253","article-title":"Immunotherapy of distant metastatic disease","volume":"20","author":"Schadendorf","year":"2009","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD011123.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/annonc\/mdt580","article-title":"Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study","volume":"25","author":"Schadendorf","year":"2014","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD011123.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ejca.2015.03.004","article-title":"Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma","volume":"51","author":"Schadendorf","year":"2015","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"issue":"22","key":"10.1002\/14651858.CD011123.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.molonc.2011.03.002","article-title":"Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care","volume":"5","author":"Scolyer","year":"2011","journal-title":"Molecular Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00008390-199902000-00007","article-title":"The chemoresistance of human malignant melanoma: an update","volume":"9","author":"Serrone","year":"1999","journal-title":"Melanoma Research"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/bjc.2013.298","article-title":"Q-TWiST analysis comparing ipilimumab\/dacarbazine vs placebo\/dacarbazine for patients with stage III\/IV melanoma","volume":"109","author":"Sherrill","year":"2013","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD011123.pub2-BIB0266|cit266","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0267|cit267","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004835.pub2","article-title":"Surgical excision margins for primary cutaneous melanoma","author":"Sladden","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD011123.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0269|cit269","unstructured":"Stata StataCorp 2017"},{"issue":"7","key":"10.1002\/14651858.CD011123.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1470-2045(06)70758-6","article-title":"Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma","volume":"7","author":"Stevens","year":"2006","journal-title":"Lancet Oncology"},{"issue":"12","key":"10.1002\/14651858.CD011123.pub2-BIB0271|cit271","first-page":"1234","article-title":"Interleukin-2 for the treatment of melanoma","volume":"6","author":"Tarhini","year":"2005","journal-title":"Current opinion in Investigational Drugs"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD011123.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"vi22","DOI":"10.1093\/annonc\/mdp257","article-title":"Surgery and radiotherapy in the treatment of cutaneous melanoma","volume":"20","author":"Testori","year":"2009","journal-title":"Annals of Oncology"},{"issue":"14","key":"10.1002\/14651858.CD011123.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0959-8049(02)00182-X","article-title":"Measuring the clinical response. What does it mean?","volume":"38","author":"Therasse","year":"2002","journal-title":"European Journal of Cancer"},{"issue":"9687","key":"10.1002\/14651858.CD011123.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0140-6736(09)61397-0","article-title":"Cutaneous melanoma in the era of molecular profiling","volume":"374","author":"Thompson","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"7","key":"10.1002\/14651858.CD011123.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1245\/s10434-013-2881-1","article-title":"Stage IV melanoma: completely resectable patients are scarce","volume":"20","author":"Wevers","year":"2013","journal-title":"Annals of Surgical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1536867X1101100206","article-title":"Multivariate random-effects meta-regression: Updates to mvmeta","volume":"11","author":"White","year":"2011","journal-title":"Stata Journal"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"4","key":"10.1002\/14651858.CD011123.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata Journal"},{"key":"10.1002\/14651858.CD011123.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"i3421","DOI":"10.1136\/bmj.i3421","article-title":"NICE approves immunotherapy combination for advanced melanoma","volume":"353","author":"Wise","year":"2016","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD011123.pub2-BIB0281|cit281","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001215","article-title":"Systemic treatments for metastatic cutaneous melanoma","author":"Crosby","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011123.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:22:21Z","timestamp":1719793341000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011123.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Skin Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":281,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011123.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,6]]}}}